Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCND3 | P30281 | 3/20 | 0.42 |
| ▸ | CDK9 | P50750 | 3/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956900 | 0.89 | TNK2 (0.58) | TNK2MAPTMAPK1SRCIGF1R | |
| SCHEMBL2957977 | 0.88 | TNK2 (0.46) | TNK2CDK4CCND1JAK2JAK3 | |
| SCHEMBL2955937 | 0.83 | SRC (0.52) | TNK2JAK2JAK3PTK2MAPT | |
| SCHEMBL2949189 | 0.81 | TNK2 (0.46) | TNK2CDK4CCND1CCNA2CDK2 | |
| SCHEMBL2952193 | 0.77 | TNK2 (0.64) | TNK2CDK4CCND1JAK2JAK3 | |
| SCHEMBL2953363 | 0.77 | TNK2 (0.64) | TNK2CDK4CCND1JAK2JAK3 | |
| SCHEMBL2959696 | 0.77 | TNK2 (0.58) | TNK2EGFRSRC | |
| SCHEMBL30338566 | 0.76 | TNK2 (0.81) | TNK2JAK3CCNKCCNA2CDK2 | |
| SCHEMBL2953623 | 0.76 | TNK2 (0.57) | TNK2CCNA2CDK2EGFRSRC | |
| SCHEMBL2955951 | 0.71 | TNK2 (0.42) | TNK2SRCIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1926734-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | Amgen Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | TNK2 113/4885CDK4 200/4885CCND1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.